ALTME.PA PAR
TME Pharma N.V.
1W: -1.9%
1M: -8.0%
3M: +48.2%
YTD: +26.5%
1Y: +1.0%
3Y: -93.9%
5Y: -99.7%
€0.10 ($0.12)
+0.00 (+0.19%)
Weekly Expected Move ±9.8%
€0
€0
€0
€0
€0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$5M
+17.8% ▲
Capital Expenditures
$16K
+15.8% ▲
5Y CAGR: +0.0%
Free Cash Flow
-$5M
+17.8% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$2K
-100.0% ▼
Net Change in Cash
$995K
+141.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$10M | -$14M | -$15M | -$7M | -$6M |
| Depreciation & Amort. | $63K | $66K | $92K | $144K | $78K |
| Stock-Based Comp. | $162K | $475K | $589K | $396K | $312K |
| Change in Working Capital | $363K | $407K | -$720K | -$555K | $217K |
| Other Non-Cash Items | $5M | $1M | $3M | $1M | $481K |
| Operating Cash Flow | -$5M | -$12M | -$12M | -$6M | -$5M |
| — Investing Activities — | |||||
| Capital Expenditures | -$39K | -$14K | -$21K | -$19K | -$16K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | -$4M | $0 | $0 | $0 | -$5K |
| Investment Sales | $4M | $0 | $0 | $0 | $0 |
| Other Investing | $0 | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$39K | -$14K | -$21K | -$19K | -$21K |
| — Financing Activities — | |||||
| Net Debt Issuance | $6M | $4M | $7M | -$39K | -$1M |
| Stock Repurchased | -$4K | -$1K | -$29K | -$1K | -$2K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$354K | -$66K | -$202K | -$74K | -$464K |
| Financing Cash Flow | $14M | $11M | $7M | $3M | $6M |
| Net Change in Cash | $9M | -$848K | -$5M | -$2M | $995K |
| Cash End of Period | $10M | $9M | $5M | $2M | $3M |
| Free Cash Flow | -$5M | -$12M | -$12M | -$6M | -$5M |